While reverse vaccinology has accelerated the identification of new antigenic epitopes on infectious agents, tumors and allergens, as well as expanded the development of broadly neutralizing monoclonal antibodies, the current limiting factor is the conversion of these antigenic epitopes into efficient immunogens deliverable as vaccines. VLP Biotech, Inc. has developed a hybrid virus-like-particle (VLP) technology for this purpose. This VLP technology represents a major advancement in medicine because it generates higher levels of therapeutic or prophylactic antibodies compared to other subunit vaccines. Further, the predominant limitations of hybrid-VLP platforms to date have been: (1) instability upon insertion of foreign epitopes and (2) the conformational requirements of nonlinear epitopes. Using our Combinatorial VLP Technology both these obstacles have been overcome. Eliciting stronger immune responses will allow us to achieve successful clinical outcomes with fewer immunizations than required by other subunit vaccines.

Summary of Advantages:

Images courtesy of Princeton University & National Center for Biotechnology Information, U.S. National Library of Medicine.
© 2005-2016 VLP Biotech, Inc.